Slide 1: Interim Results for the Period Ending 30 June 2024 and Business Update
Interim Results for the Period Ending 30 June 2024 and Business Update Christina Coughlin, CEO 30th September 2024 © Avacta Group plc 2024
Slide 2: Disclaimer
Disclaimer For the purposes of this disclaimer, this “presentation” shall mean and include the slides that follow, the oral presentation of the slides by Avacta Group plc (the “Company”) or any person on its behalf, any question-and-answer session that follows the oral presentation, hard copies (inc
Slide 3: Avacta Group plc Interim Financial Results
Avacta Group plc Interim Financial Results for the Period Ending 30 June 2024 30 September 2024 3 © Avacta Group plc 2024
Slide 4: Interim Results for the Six Months Ending June 2024: Key Messages
Interim Results for the Six Months Ending 30 June 2024 Key Messages H1 2024 (£m) H1 2023 (£m) • Performance of group was in line with Board Revenue 11.3 11.9 expectations Therapeutics* 0.1 2.0 • Increased revenue and gross profit of the Diagnostics division. Diagnostics 11.2 9.9 Gross profit 5.0 6.7
Slide 5: Interim Results: Cashflow Analysis
Interim Results for the Six Months Ending 30 June 2024 Cashflow Analysis H1 2024(£m) • Operating activities – cash inflow from Cash at 31 December 2023 16.6 Diagnostics of £1.0m from operating Net cash from / (used in) operating activities (12.4) activities Diagnostics 1.0 Therapeutics (8.0) • Finan
Slide 6: Business Update
Business Update 30 September 2024 6 © Avacta Group plc 2024
Slide 7: Avacta Business Update: Summary of Highlights
Avacta Business Update: Summary of Highlights • The pre|CISION enabled peptide drug conjugate AVA6000 continues to demonstrate a highly encouraging tolerability profile with robust preliminary efficacy signals in both study arms of Phase 1a trial • The ongoing expansion cohorts will further refine o
Slide 8: pre|CISION-Enabled Warheads are Released Specifically in the TME to Optimize Delivery
pre|CISION-Enabled Warheads are Released Specifically in the TME to Optimize Delivery pre|CISION Peptide Drug Conjugates (PDC) pre|CISION Biologic Drug Conjugates The pre|CISION peptide is added to a warhead to create a peptide drug The pre|CISION platform is used as a warhead release mechanism in a
Slide 9: The Spatial Organization of the TME Supports the pre|CISION Bystander Effect Delivery
The Spatial Organization of the TME Supports the pre|CISION Bystander Effect Delivery In the TME, CAFs with the highest expression of FAP are concentrated at the tumor-stroma interface and co- located with the blood vessels which delineates the “bystander effect” delivery High-power image of the tum
Slide 10: The Evolution of pre|CISION Chemistry Results in Optimized Kcat/Km and Tumor PK
The Evolution of pre|CISION Chemistry Results in Optimized Kcat/Km and Tumor PK FIRST GEN SECOND GEN THIRD GEN pre|CISION with no spacer or PK pre|CISION with extended chemistry and pre|CISION Biologic Conjugate Drug extensions increased half life FAP-enabled MMAE with PEG Cap/Maleimide/ AVA6000 (FA
Slide 11: Gen 1 pre|CISION: FAP-enabled doxorubicin (AVA6000)
Gen 1 pre|CISION: FAP-enabled doxorubicin (AVA6000) AVA6000 delivers high concentrations of doxorubicin to the TME relative to plasma, resulting in durable tumor shrinkage in patients whose tumors have (1) over-expression of FAP and (2) sensitivity to the anthracycline mechanism Exposure-response mo
Slide 12: AVA6000 Trial Design and Patient Population
AVA6000 Trial Design and Patient Population PHASE 1: ARM 1 Q3W iv 80 [54] 120 [81] 160 [108] 200 [135] 250 [169] 310 [209] 385 [260] [dox equivalent] N=4 N=6 N=8 N=7 N=9 N=6 N=4 (mg/m2) Conventional dox [75 mg/m2] escalated dose doxorubicin Efficacy assessment every 6 weeks PHASE 2 PHASE 1: ARM 2 Re
Slide 13: AVA6000 Has Reduced Severe Hematologic Toxicities Compared to Conventional Doxorubicin
AVA6000 Has Reduced Severe Hematologic Toxicities Compared to Conventional Doxorubicin 49% Neutropenia 14% 23.7% Leukopenia 7% BONE MARROW TOXICITY Severe hematologic toxicities Febrile 16.5% limit the dosing of cytotoxic Neutropenia 0% drugs in the clinic AVA6000 is capable of significantly reducin
Slide 14: AVA6000 Lacks Severe Cardiac Toxicity Associated with Conventional Doxorubicin
AVA6000 Lacks Severe Cardiac Toxicity Associated with Conventional Doxorubicin Severe cardiac toxicity Mild cardiac toxicity (Gr 3/4 cardiomyopathy/ (left ventricular ejection cardiac dysfunction) fraction dysfunction)2 CARDIAC TOXICITY AVA6000^ 0% AVA6000^ 1.8% Known cumulative toxicity of conventi
Slide 15: AVA6000 Reduces Toxicities that Impact the Quality of Life v. Conventional Doxorubicin
AVA6000 Reduces Toxicities that Impact the Quality of Life v. Conventional Doxorubicin AVA6000 Doxorubicin1 Q2W (160-250 mg/m2, n=13) 75 mg/m2 Q3W (80-385 mg/m2, n=44) N=249 38.5 Q2W Nausea 66.7 34.1 Q3W 7.7 Mucositis/ QUALITY OF LIFE stomatitis 6.8 40.6 Multiple toxicities that impact the QoL for p
Slide 16: AVA6000: Best Response on Study in Patients with FAP high Indications
AVA6000: Best Response on Study in Patients with FAP high Indications 40 20 disease sum of the longest diameters progression Best percent change in the * * * * * * * * 0 -20 H partial response -40 H -60 -80 Undifferentiated pleomorphic sarcoma Salivary gland cancer Liposarcoma Other sarcoma * Pt ong
Slide 17: AVA6000: Best Response on Study in Patients with FAP high Indications
AVA6000: Best Response on Study in Patients with FAP high Indications 40 20 disease sum of the longest diameters progression Best percent change in the * * * * * * * * 0 -20 H partial response -40 Patients with salivary gland cancers have H -60 evidence of activity: 1 partial response and 1 minor re
Slide 18: AVA6000: Case Study Highlights Response with FAP-Negative Tumor Cells
AVA6000: Case Study Highlights Response with FAP-Negative Tumor Cells Case Study : 79 –year-old male with SGC tumor tumor (ductal histology) Prior therapy: triptorelin/ bicalutamide vessels followed by disease progression Enrolled in the AVA6000 trial (Oct 2023) in the 385 mg/m2 Q3W cohort; Oct 2023
Slide 19: AVA6000: Best Response on Study in Patients with FAP high Indications
AVA6000: Best Response on Study in Patients with FAP high Indications 40 20 disease sum of the longest diameters progression Best percent change in the * * * * * * * * 0 -20 H partial response -40 Patients with high grade sarcomas have evidence H -60 of activity: 2 partial responses, 1 minor respons
Slide 20: AVA6000: Case Study Highlights a Deepening RECIST Response in Treatment-Resistance
AVA6000: Case Study Highlights a Deepening RECIST Response in Treatment-Resistance Case Study 1: Near complete 60-year-old male patient diagnosed with an undifferentiated resolution of the pleomorphic sarcoma (UPS) multiple pleural Treated initially with local control measures (surgery and radiation
Slide 21: AVA6000 Results in Concentration of Doxorubicin in the Tumor Regardless of FAP Level
AVA6000 Results in Concentration of Doxorubicin in the Tumor Regardless of FAP Level Warhead (free doxorubicin) Concentration 24 hr After the First FAP Level of Activity Does NOT Correlate Dose of AVA6000 with Concentration of Released Warhead Patients with FAPhigh 10000 24 hours post-dose assessmen
Slide 22: AVA6000 Results in Concentration of Doxorubicin in the Tumor Regardless of FAP Level
AVA6000 Results in Concentration of Doxorubicin in the Tumor Regardless of FAP Level Warhead (free doxorubicin) Concentration 24 hr After the First Patient Populations Addressable by Dose of AVA6000 pre|CISION technology 10000 Patients with FAPhigh (any warhead) Patients with FAPmid FAPhigh Salivary
Slide 23: AVA6000: Summary and Conclusions
AVA6000: Summary and Conclusions • AVA6000 is safe and well-tolerated in both the Q3W and Q2W schedules with preliminary evidence of efficacy and early limited cardiac safety signal. No MTD was determined in the trial despite dosing up to 385 mg/m2 every 3 weeks (~4x conventional dose doxorubicin) •
Slide 24: AVA6000: Clinical Development Strategy and Planning
AVA6000: Clinical Development Strategy and Planning PROGRAM Phase I (Q3W/Q2W) Ph I Dose Escalation Data Release: 2H 2024 Q2W/Q3W RP2D and Indications Phase 1 Expansion Cohort 1 Escalation and Expansions Expansion Cohort 2 Expansion Cohort 3 * Ph Ib Expansions: 2H 2024 Phase 2 Phase 2 Trial (single i
Slide 25: pre|CISION PDC Have Key Advantages Over Traditional ADC Approaches
pre|CISION PDC Have Key Advantages Over Traditional ADC Approaches Avacta Traditional pre|CISION Peptide Drug Conjugate v. Antibody Drug Conjugate pre|CISION medicines leverage the bystander Warhead is released intracellularly after ADC Mechanism effect to kill both FAP+ and FAP- cells internalizati
Slide 26: Avacta: Completed and Upcoming Milestones in 2H 2024
Avacta: Completed and Upcoming Milestones in 2H 2024 Initiate Expansion Update AVA6000 Release Pipeline Host R&D Spotlight Cohorts Clinical Data Update Science Day Completing the Phase Updating the AVA6000 Release of the Review of the 1 dose escalation and clinical data to support updated pipeline o
Slide 27: Avacta: Setting Goals for the Pipeline into 2025
Avacta: Setting Goals for the Pipeline into 2025 AVA6000: AVA6000: Next Gen preCISION: Expansion Cohort data Phase 2 Trial Candidate selection Preliminary data in the The clinical candidate The AVA6000 Phase 2 ongoing expansion for the next pre|CISION trial is planned to cohorts will be medicine wil
Slide 28: © Avacta’|
© Avacta’|